Matzke G R, Sawchuk R J
Drug Intell Clin Pharm. 1981 May;15(5):386-8. doi: 10.1177/106002808101500510.
A patient with chronic renal failure did not respond to "therapeutic" serum phenytoin concentrations as measured by enzyme-multiplied immunoassay (EMIT). Her seizure disorder was not controlled despite phenytoin concentrations of 25-35 micrograms/ml. When her serum samples were reassayed by high pressure liquid chromatography and gas-liquid chromatography, the phenytoin serum concentrations were found to be approximately 1/2 of the previously reported values, that is, 16.0 micrograms/ml vs. 33 micrograms/ml. The precise reason for this discrepancy is currently unknown. Our findings suggest that the EMIT assay may yield falsely elevated serum phenytoin concentrations in uremic subjects.
一名慢性肾衰竭患者,其血清苯妥英浓度经酶放大免疫测定法(EMIT)检测处于“治疗”水平,但却没有出现相应疗效。尽管苯妥英浓度在25 - 35微克/毫升之间,她的癫痫病症仍未得到控制。当采用高压液相色谱法和气液色谱法对其血清样本重新检测时,发现苯妥英血清浓度约为先前报告值的1/2,即16.0微克/毫升对比33微克/毫升。目前尚不清楚造成这种差异的确切原因。我们的研究结果表明,EMIT测定法可能会使尿毒症患者的血清苯妥英浓度出现假性升高。